Latham & Watkins Advises on Structure Therapeutics Upsized US$650 Million Public Offering of ADSs and Pre-Funded Warrants

Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, has announced the pricing of its upsized underwritten public offering of 8,461,538 American depositary shares (ADSs), each representing three ordinary shares, at a price to the public of US$65 per ADS and pre-funded warrants to purchase 1,538,462 ADSs at a price to the public of US$64.9999 per pre-funded warrant. All of the securities in the offering are being sold by Structure Therapeutics.

Latham & Watkins represents the underwriters in the offering with a Capital Markets team led by San Diego partner Matt Bush and counsel Anthony Gostanian, with associates Rachel Staub and Madeline Hodges.